20n
20n, based in San Francisco, CA, is a healthcare company specializing in industrial biotechnology. It provides an open-source platform for synthetic biology and offers a Bioreachables Service with DNA blueprints for various molecules.
Company Overview
20n is a San Francisco-based biotechnology company, situated in the healthcare sub-industry of industrial bio. Despite its currently inactive status, 20n has made significant strides in synthetic biology. The company focuses on sequencing, synthesis, and computational systems for DNA design, aiding the biotech revolution through innovative approaches utilizing machine learning, distributed systems, AI planning, program synthesis, data mining, and natural language processing. Supported by DARPA, 20n aims to serve firms transitioning to sustainable biological manufacturing processes.
Open-Source Platform for Synthetic Biology
20n provides an open-source platform named 20n/act, which is available on GitHub. The 20n/act platform serves as a data mining and prediction stack designed for creating DNA sequences to produce specific molecules from sugar. The platform allows industrial biotech firms to implement sustainable biological manufacturing processes by leveraging computational tools to design novel DNA sequences efficiently.
Bioreachables Service
20n's Bioreachables Service consists of two editions: the Preview Edition and the Enterprise Edition. The Preview Edition includes pathway data for 11 selected molecules, DNA designs, functional terms of identified uses, patents, and physiochemical properties. In contrast, the Enterprise Edition offers comprehensive data on over 10,000 molecules, DNA designs, IP ownership, patents, physiochemical properties, and exclusive access for scientists. The Enterprise Edition also features advanced search capabilities by substructure and function, including drug APIs, flavors, fragrances, and polymers.
Y Combinator W15 Batch
20n was part of the Y Combinator W15 batch, signifying its inclusion in a highly competitive and prestigious startup accelerator program. Participation in Y Combinator provided the company with early-stage funding, mentorship, and a broad network of industry connections, facilitating its growth and development in the synthetic biology sector.
Industrial Biotechnology Applications
20n focuses on industrial biotechnology applications across several sectors including advanced fuels, materials, therapeutics, flavors, and fragrances. The company has developed a computational system for predicting DNA edits, which plays a crucial role in these sectors by enabling the design of tailored DNA sequences. One notable achievement includes the invention of organisms capable of producing acetaminophen (Tylenol) through sugar fermentation, showcasing 20n's potential in pharmaceutical applications.